New ACC/AHA guidelines provide updated recommendations for dyslipidemia management, focusing on atherogenic lipoproteins and ...

The AHA and ACC have recently updated the guidelines for the management of high blood cholesterol. The changes emphasize ...

High-density lipoprotein cholesterol (HDL-C) has long been considered “good cholesterol,” with higher levels associated with ...

A new pill, enlicitide, reduced LDL (“bad”) cholesterol by about 60% in a large clinical trial, matching the power of ...

Doctors should begin screening for heart disease and treating people for high cholesterol levels even younger than before, ...

The latest cholesterol guidelines include three new screening tests: coronary artery calcium, lipoprotein (a), and ...

American College of Cardiology (ACC), and nine other leading medical organizations have released updated guidelines for ...

Individuals with a higher risk of heart disease should ideally start testing for low-density lipoprotein (LDL) cholesterol at age 10. Also, everyone should strive for an LDL level below 100. This is ...

Compared with placebo, obicetrapib lowered LDL-C by 33% at day 84 (P .0001). Topline results were announced from a phase 3 trial evaluating obicetrapib, an investigational low dose cholesterol ester ...

TORONTO, March 5, 2026 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and ...

In another study of dyslipidemic patients not treated with hypolipidemic drugs (baseline examination), a very good correlation between LDL-C and apoB (r = 0.903; p < 0.001) was found. [66] In spite of ...

The ACC and AHA released updated guidelines for the management of dyslipidemia to reduce risk for atherosclerotic ...